Evonik has rejected a reported €10.3 billion approach from BASF, equivalent to about €22.15 a share, as too low. The response does not erase the industrial logic behind a combination. It puts a price on how difficult that logic will be to realise.BASF confirmed exploratory talks on 25 September but has not disclosed an offer price. It says valuation depends on synergies that can be verified only with Evonik's cooperation. Evonik and its 44% shareholder RAG-Stiftung have not entered formal talks.
Scale answers some of the industry's pressure
German chemicals groups face high energy costs, weak European demand and larger Asian competitors. Evonik's specialty plastics, feed additives and ingredients could complement BASF's broader portfolio and increase the share of customer-facing businesses.Reported estimates put potential annual cost savings near €700 million. Those benefits are not cash on signing. They depend on integration, asset choices and regulatory clearance, and they often arrive alongside restructuring costs.
A national champion can still destroy national capacity
Consolidation can spread research, procurement and fixed costs across a larger revenue base. It can also remove overlapping jobs and sites without solving the energy and demand problems that weakened the companies in the first place.German Business Review's conclusion is that BASF must present an industrial plan, not merely a synergy number. RAG-Stiftung, employee representatives and regulators will want commitments on investment, headquarters, research and the future of plants before treating size as resilience.Evonik's rejection strengthens that bargaining position. If BASF raises its price, the financial return becomes more dependent on synergies. If it walks away, the pressure for portfolio change and sector consolidation remains.
The next move must make the operating case visible
Watch whether Evonik grants due diligence, whether RAG-Stiftung supports engagement, and which product overlaps attract antitrust scrutiny. Any revised proposal should separate cost savings from revenue assumptions.The deal may be strategically plausible. That does not make the first price sufficient or the integration low-risk.
How to use this analysis
Company reporting needs a consistent bridge from operating activity to accounting results. Orders, deliveries, revenue, profit and cash can belong to different periods. Group figures can also cover operations far beyond the place attached to the story, so local economic claims require a separate location-specific source.
Source and verification note
The reporting base for this article is BASF: Exploratory talks regarding potential takeover of Evonik and Reuters: Evonik rejects €10.3 billion BASF bid. The link is provided to the source page or release so readers can check the reporting period, definitions and later revisions. Figures are not extended beyond the source's geographic or institutional scope, and forecasts remain labelled as expectations until an official release records the outcome.